Naloxegol (Movantik ®) Provides Rapid Response and Sustained Improvement of Opioid-Induced Constipation Symptoms in Older Adults
Naloxegol (Movantik ®), an oral peripherally acting mu-opioid receptor antagonist (PAMORA) has demonstrated rapid and predictable relief of OIC in patients treated with opioids for chronic non-cancer pain in two phase 3 trials (KODIAC 4/5; NCT01309841/NCT01323790). In subjects ≥65 yrs, naloxegol (25mg, 12.5mg) demon strated significantly better response rates, clinically relevant early symptom relief, and predictable efficacy compared with PBO. Improvements in SBMs, CSBMs, straining, and stool consistency were rapid and sustained across 12 weeks.
Source: Pain Management Nursing - Category: Nursing Authors: Charles McLeskey, Darren Brenner, Carol Rockett, Mansi Jamindar, Enoch Bortey, Martin Hale, Theresa Mallick-Searle Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Pain | Constipation | Nurses | Nursing | Oral Cancer | Pain | Pain Management